Age (years) |
54±2.5 |
44±3.9 |
0.03 |
Gender (male) - no.(%) |
26(79) |
11(65) |
0.28 |
QRS duration (ms) |
123±7.3 |
117±10 |
0.61 |
NYHA Class I - no.(%)* |
13(41) |
8(47) |
|
II - no.(%) |
15(47) |
6(35) |
0.51 |
III - no.(%) |
4(13) |
2(12) |
|
IV - no.(%) |
0 (0) |
1 (6) |
|
LVEF (%) |
33±1.8 |
51±3.1 |
<0.001 |
Diabetes Mellitus - no.(%) |
2(6) |
0(0) |
0.30 |
Atrial fibrillation - no.(%) |
11(33) |
4(24) |
0.47 |
Syncope - no.(%) |
11(33) |
6(35) |
0.89 |
Amiodarone - no.(%) |
3(9) |
2(12) |
0.77 |
Beta blocker - no.(%) |
22(67) |
7(41) |
0.08 |
ACE/ARB - no.(%) |
26(79) |
7(41) |
0.008 |
Aldosterone antagonist - no.(%) |
6(18) |
1(6) |
0.24 |
R2I2 |
1.00±0.06 |
0.96±0.08 |
0.67 |
R2I2≥1.03 - no.(%) |
13(39) |
6(35) |
1.00 |
PERS |
1.13[0.58] |
1.39[0.93] |
0.20 |
PERS≥1.21 - no.(%) |
14(42) |
10(59) |
0.37 |
Negative R2I2+PERS - no.(%) |
11(33) |
6(35) |
|
Either R2I2/PERS - no.(%) |
17(52) |
6(35) |
0.41 |
Positive R2I2+PERS - no.(%) |
5(15) |
5(30) |
|
Follow up time (years) |
5.80[1.0] |
5.05[2.2] |
0.22 |